InspireMD Inc (NSPR)
0.6195
+0.02 +3.01%
NYSE AM
Jan 19, 20:00
USD
View All Key Stats
Key Stats
Income Statement | |
Revenue (TTM) | 3.34M |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (TTM) | -1.26 |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Net Income (TTM) | -9.248M |
Profitability | |
Gross Profit Margin (Quarterly) | 30.41% |
Profit Margin (Quarterly) | -227.9% |
Dividend | |
Dividend Yield (Forward) | Upgrade |
Dividend Yield | 0.00% |
Price and Valuation | |
Market Cap | 22.89M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
PS Ratio | 2.602 |
PE Ratio | -- |
Price to Book Value | 2.030 |
Other | |
Beta (5Y) | Upgrade |
Debt to Equity Ratio | 0.00 |
Free Cash Flow (Quarterly) | -3.07M |
Return on Equity | Upgrade |
View All NSPR News
News
-
WireHeadlineTime (ET)
-
PR Newswire01/11 09:31
-
Yahoo11/29 14:33
-
Yahoo11/11 07:14
-
MT Newswires11/09 06:34
-
SA Breaking News11/09 06:31
-
Yahoo11/03 07:53
-
MT Newswires10/16 12:52
-
PR Newswire09/08 10:40
-
MT Newswires09/08 09:06
-
MT Newswires09/08 07:52
-
SA Breaking News09/08 07:12
-
Accesswire08/31 17:00
-
SA Breaking News08/10 06:41
-
SA Breaking News08/05 06:46
-
MT Newswires08/05 06:42
-
MT Newswires07/23 15:35
-
SA Breaking News07/23 09:36
-
MT Newswires07/23 09:10
-
PR Newswire06/10 11:00
-
MT Newswires06/03 15:58
Fundamentals
Income Statement View Statement
Ratings & Reports
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
- One Page Report Download
Advertisement
Edit
Profile
- URL: http://www.inspiremd.com
- Investor Relations URL: http://www.inspiremd.com/en/investors/investor-relations/
- HQ State/Province: N/A
- Sector: Healthcare
- Industry: Medical Devices
- Equity Style: Small Cap/Value
- Next Earnings Release: N/A
- Last Earnings Release: Aug. 05, 2015
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: N/A
- Description: InspireMD Inc is the United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Germany, Italy, Belarus, Brazil, and other countries.
Analyst Coverage
Consensus Recommendations | |
Buy Recommendations | Upgrade |
Outperform Recommendations | Upgrade |
Hold Recommendations | Upgrade |
Underperform Recommendations | Upgrade |
Sell Recommendations | Upgrade |
Consensus Recommendation | Upgrade |
Consensus Rating | Upgrade |
Target Price | |
Price | 0.6195 |
Price Target | Upgrade |
Price Target Upside (Daily) | Upgrade |
Other Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- NSPR Tweets Stocktwits
Advertisement